388 related articles for article (PubMed ID: 26038275)
1. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma?
Goda JS; Lewis S; Agarwal A; Epari S; Churi S; Padmavati A; Gupta T; Shetty P; Moiyadi A; Jalali R
Clin Neurol Neurosurg; 2015 Aug; 135():46-53. PubMed ID: 26038275
[TBL] [Abstract][Full Text] [Related]
2. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
3. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
5. The impact of sequential vs. combined radiochemotherapy with temozolomide, resection and MGMT promoter hypermethylation on survival of patients with primary glioblastoma--a single centre retrospective study.
Rapp M; Goeppert M; Felsberg J; Steiger HJ; Sabel M
Br J Neurosurg; 2013 Aug; 27(4):430-5. PubMed ID: 23418781
[TBL] [Abstract][Full Text] [Related]
6. Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival.
Babu R; Komisarow JM; Agarwal VJ; Rahimpour S; Iyer A; Britt D; Karikari IO; Grossi PM; Thomas S; Friedman AH; Adamson C
J Neurosurg; 2016 Apr; 124(4):998-1007. PubMed ID: 26452121
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
8. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
[TBL] [Abstract][Full Text] [Related]
9. Cerebellar glioblastoma multiforme: a retrospective study of 28 patients at a single institution.
Yang S; Liu J; Wang T; Li X; You C
Int J Neurosci; 2013 Oct; 123(10):691-7. PubMed ID: 23550813
[TBL] [Abstract][Full Text] [Related]
10. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.
Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280
[TBL] [Abstract][Full Text] [Related]
11. Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.
Kim BS; Seol HJ; Nam DH; Park CK; Kim IH; Kim TM; Kim JH; Cho YH; Yoon SM; Chang JH; Kang SG; Kim EH; Suh CO; Jung TY; Lee KH; Kim CY; Kim IA; Hong CK; Yoo H; Kim JH; Kang SH; Kang MK; Kim EY; Kim SH; Chung DS; Hwang SC; Song JH; Cho SJ; Lee SI; Lee YS; Ahn KJ; Kim SH; Lim DH; Gwak HS; Lee SH; Hong YK
Cancer Res Treat; 2017 Jan; 49(1):193-203. PubMed ID: 27384161
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
[TBL] [Abstract][Full Text] [Related]
13. Pediatric glioblastoma with oligodendroglioma component: aggressive clinical phenotype with distinct molecular characteristics.
Mizoguchi M; Hata N; Suzuki SO; Fujioka Y; Murata H; Amano T; Nakamizo A; Yoshimoto K; Iwaki T; Sasaki T
Neuropathology; 2013 Dec; 33(6):652-7. PubMed ID: 23530875
[TBL] [Abstract][Full Text] [Related]
14. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
15. Can elderly patients with newly diagnosed glioblastoma be enrolled in radiochemotherapy trials?
Fiorentino A; Balducci M; De Bonis P; Chiesa S; De Filippo L; Mangiola A; De Rose F; Autorino R; Rinaldi C; Fersino S; Diletto B; Matteucci P; Ciurlia E; Fusco V; Anile C; Valentini V
Am J Clin Oncol; 2015 Feb; 38(1):23-7. PubMed ID: 23388566
[TBL] [Abstract][Full Text] [Related]
16. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial.
Hegi ME; Janzer RC; Lambiv WL; Gorlia T; Kouwenhoven MC; Hartmann C; von Deimling A; Martinet D; Besuchet Schmutz N; Diserens AC; Hamou MF; Bady P; Weller M; van den Bent MJ; Mason WP; Mirimanoff RO; Stupp R; Mokhtari K; Wesseling P; ;
Acta Neuropathol; 2012 Jun; 123(6):841-52. PubMed ID: 22249618
[TBL] [Abstract][Full Text] [Related]
17. Outcome of conventional treatment and prognostic factor in elderly glioblastoma patients.
Oh SW; Jee TK; Kong DS; Nam DH; Lee JI; Seol HJ
Acta Neurochir (Wien); 2014 Apr; 156(4):641-51. PubMed ID: 24553726
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of temozolomide as adjuvant chemotherapy after postsurgical radiotherapy alone for glioblastomas.
Rhee DJ; Kong DS; Kim WS; Park KB; Lee JI; Suh YL; Song SY; Kim ST; Lim DH; Park K; Kim JH; Nam DH
Clin Neurol Neurosurg; 2009 Nov; 111(9):748-51. PubMed ID: 19716649
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and survival in primary glioblastoma patients treated with concomitant plus adjuvant temozolomide versus adjuvant temozolomide: results of a single-institution, retrospective, matched-pair analysis.
Gutenberg A; Bock HC; Reifenberger G; Brück W; Giese A
Acta Neurochir (Wien); 2013 Mar; 155(3):429-35. PubMed ID: 23254891
[TBL] [Abstract][Full Text] [Related]
20. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis.
Minniti G; Scaringi C; Lanzetta G; Terrenato I; Esposito V; Arcella A; Pace A; Giangaspero F; Bozzao A; Enrici RM
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):109-15. PubMed ID: 25442339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
